Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, announces the completion of a funding round in which it raised EUR 2.
Polyplus-transfection plans to use the funding to upscale its research and development resources, specifically in the area of new compounds dedicated to siRNA delivery, which recently yielded significant and promising preclinical results in lung and prostate cancer models. These new research programs are additional to those in which Polyplus-transfection is already actively engaged in the area of RNA interference through its numerous partnerships with other biotechnology companies and university laboratories.
In its joint programs with third parties, Polyplus-transfection acts as a specialist in in-vivo intracellular nucleic acid transfer, a critical step in any project to develop a therapy based on RNA interference. The additional funding will enable Polyplus-transfection to significantly expand its science team. It is planning to recruit an additional 10 researchers and laboratory technicians in the short term, which will increase the total to 25, out of a total workforce of Gabriel Festoc.
In addition, these funds will enable us to develop better-defined solutions and to provide many more demonstrations of their therapeutic effects.
Never miss an update from Science Business: Newsletter sign-up. Subscribe today. Log in. Sign up for the Funding Newswire. Sign up for the Policy Bulletin. Sign up for The Widening. Why join? Become a member. This site requires JavaScript to work correctly. Please enable Javascript and reload the page.
